Literature DB >> 18958618

Sertraline hepatotoxicity: report of a case and review of the literature.

Fehmi Tabak1, Feyza Gunduz, Veysel Tahan, Omur Tabak, Resat Ozaras.   

Abstract

Sertraline is a commonly prescribed selective serotonin reuptake inhibitor drug. Hepatotoxicity caused by sertraline is rare. Asymptomatic elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels have been rarely reported and shortly normalize after discontinuation of the agent. We present a case of severe drug-induced hepatitis in a patient receiving sertraline. To our knowledge, this is the seventh case in the medical literature as being associated with severe hepatotoxicity. Since it is extremely rare, we do not suggest a strict laboratory monitoring. However, sertraline should be discontinued in cases with symptoms implying hepatotoxicity and the patients should be informed of the potential of this side effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18958618     DOI: 10.1007/s10620-008-0524-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  7 in total

1.  Acute liver damage possibly related to sertraline and venlafaxine ingestion.

Authors:  K Y Kim; W Hwang; R Narendran
Journal:  Ann Pharmacother       Date:  1999-03       Impact factor: 3.154

Review 2.  Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Authors:  C Bénichou
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

3.  Symptomatic liver injury probably related to sertraline.

Authors:  M L Hautekeete; I Colle; H van Vlierberghe; A Elewaut
Journal:  Gastroenterol Clin Biol       Date:  1998-03

Review 4.  Drug-induced liver disease.

Authors:  H J Zimmerman
Journal:  Clin Liver Dis       Date:  2000-02       Impact factor: 6.126

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 6.  Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity.

Authors:  Seth Persky; John F Reinus
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

7.  Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy.

Authors:  M M Verrico; D A Nace; A L Towers
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

  7 in total
  10 in total

1.  Sertraline hepatotoxicity: report of a case and review of the literature.

Authors:  Virginia Collados; Hacibe Hallal; Raúl J Andrade
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

2.  Sertraline induces endoplasmic reticulum stress in hepatic cells.

Authors:  Si Chen; Jiekun Xuan; Letha Couch; Advait Iyer; Yuanfeng Wu; Quan-Zhen Li; Lei Guo
Journal:  Toxicology       Date:  2014-05-24       Impact factor: 4.221

3.  Acute liver injury secondary to sertraline.

Authors:  Christopher F D Li Wai Suen; Ray Boyapati; Ian Simpson; Anouk Dev
Journal:  BMJ Case Rep       Date:  2013-09-26

Review 4.  Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity.

Authors:  Si Chen; William B Melchior; Lei Guo
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2014       Impact factor: 3.781

5.  Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Authors:  Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

Review 6.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

7.  PharmGKB summary: sertraline pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Kevin Hicks; Laura B Ramsey; Jeffrey R Strawn; D Max Smith; Margarita Bobonis Babilonia; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000

8.  HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats.

Authors:  Karolina Pytka; Monika Głuch-Lutwin; Joanna Knutelska; Magdalena Jakubczyk; Anna Waszkielewicz; Magdalena Kotańska
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

Review 9.  Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

Authors:  Diogo Telles-Correia; António Barbosa; Helena Cortez-Pinto; Carlos Campos; Nuno B F Rocha; Sérgio Machado
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06

Review 10.  Antidepressants- and antipsychotics-induced hepatotoxicity.

Authors:  Nevena Todorović Vukotić; Jelena Đorđević; Snežana Pejić; Neda Đorđević; Snežana B Pajović
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.